Vis enkel innførsel

dc.contributor.authorEdvardsen, Magnus
dc.contributor.authorHindberg, Kristian
dc.contributor.authorHansen, Ellen-Sofie
dc.contributor.authorMorelli, Vania Maris
dc.contributor.authorUeland, Thor
dc.contributor.authorAukrust, Pål
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorHoltet Evensen, Line
dc.contributor.authorHansen, John-Bjarne
dc.date.accessioned2021-10-15T09:26:07Z
dc.date.available2021-10-15T09:26:07Z
dc.date.issued2021-01-07
dc.description.abstractSeveral case-control studies have reported elevated plasma von Willebrand factor (VWF) levels in patients with venous thromboembolism (VTE) compared with controls. However, because few studies have investigated the association in a prospective design, it is unclear whether elevated plasma VWF is a risk factor or a consequence of the VTE event. Therefore, we aimed to investigate the prospective association between plasma VWF levels and risk of VTE, as well as to perform subgroup analyses of deep vein thrombosis (DVT) and pulmonary embolism. We established a population-based nested case-control study of 414 VTE cases and 843 age- and sex-matched controls based on the Tromsø study cohort (1994-2007). Blood samples were collected at cohort baseline (1994-1995). Odds ratios (ORs) with 95% confidence intervals (CIs) for VTE were estimated across quartiles of VWF levels. We found that the risk of VTE increased linearly across quartiles of VWF levels (P for trend = .023). Participants with VWF in the highest quartile had an OR of 1.45 (95% CI, 1.03-2.03) for VTE compared with those in the lowest quartile. The association was strongest for unprovoked VTE (OR, 2.74; 95% CI, 1.66-4.54) and unprovoked DVT in particular (OR, 6.73; 95% CI, 3.07-14.76). Further adjustment for body mass index, C-reactive protein, hypertension, estrogen use, and smoking had a modest effect on the risk estimates. To conclude, we found a dose-dependent relationship between plasma VWF levels and future risk of incident VTE, and unprovoked events in particular. Our findings suggest that VWF may represent a promising biomarker for future risk of incident VTE.en_US
dc.identifier.citationEdvardsen, Hindberg, Hansen, Morelli, Ueland, Aukrust, Brækkan, Holtet Evensen, Hansen. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Advances. 2021;5(1):224-232en_US
dc.identifier.cristinIDFRIDAID 1902804
dc.identifier.doi10.1182/bloodadvances.2020003135
dc.identifier.issn2473-9529
dc.identifier.issn2473-9537
dc.identifier.urihttps://hdl.handle.net/10037/22769
dc.language.isoengen_US
dc.publisherAmerican Society of Hematologyen_US
dc.relation.ispartofEdvardsen, M.S. (2024). Plasma von Willebrand factor and risk of future venous thromboembolism. (Doctoral thesis). <a href=https://hdl.handle.net/10037/33570>https://hdl.handle.net/10037/33570</a>.
dc.relation.journalBlood Advances
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Dermatology and venereology: 753en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Dermatologi og venerologi: 753en_US
dc.titlePlasma levels of von Willebrand factor and future risk of incident venous thromboembolismen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel